
# **IRRITABLE BOWEL SYNDROME (IBS) DIAGNOSTIC PATHWAY1-6**



The Rome Foundation suggests for clinical practice, a diagnosis may be made with a lower symptom frequency and a shorter duration (8 weeks or more) than those required above, provided that symptoms are bothersome for the patient (i.e., interfering with daily activities/quality of life) and there is clinical confidence that other diagnoses have been sufficiently ruled out.<sup>7</sup>



© 2022 AbbVie and Ironwood Pharmaceuticals, Inc. All rights reserved. Ironwood® and its three-leaf design are registered trademarks of Ironwood Pharmaceuticals, Inc. ABBV-US-00715-MC October 2022 \*Patients who meet the diagnostic criteria for IBS but whose bowel habits cannot be accurately categorized into one of these three groups should be categorized as IBS-Unclassified. Adapted with permission from © 2006 Rome Foundation. This diagnostic pathway is provided as a reference tool only and is not a substitute for clinical judgment. Each healthcare provider is solely responsible for any decisions made or actions taken in reliance of this information.

## A PATIENT ASSESSMENT

#### PATIENT HISTORY

#### Symptom history

- Predominant or most bothersome symptom(s) (e.g., diarrhea, pain, bloating)
- · Symptom triggers (e.g., relationship to food, stress, physical activity)
- · Dietary habits (e.g., intake of caffeine, sodas, poorly absorbed carbohydrates)
- · Impact of symptoms on daily quality of life

#### Comorbidity

- · Other medical conditions (e.g., diabetes, lupus)
- Other gastrointestinal (GI) disorders (e.g., dyspepsia, GERD)
- · Other functional non-GI disorders (e.g., fibromyalgia)
- · Psychiatric comorbidity

#### Previous investigations and treatments

- · Prior GI-related investigations and results
- Prior interventions, or medications (over-the-counter or prescription) used and responses

#### Personal history and expectations

- Prior abuse history/psychological distress
- Patient's goals and expectations

#### PHYSICAL EXAM

- Generally normal in patients with IBS
- Rectal exam may elicit co-existing defecatory disorder
- Pelvic exam important if co-existing pelvic pain

### **B** ADDITIONAL TESTS AND DIFFERENTIAL DIAGNOSES

#### DIAGNOSTIC TESTS FOR IBS

- If not previously performed, complete blood count should be considered
- Celiac serology, C-reactive protein, and fecal calprotectin may be considered, particularly for patients with symptoms of IBS-D or IBS-M
- In the absence of alarm features, additional tests are NOT required to make an affirmative IBS diagnosis
- The symptom-based Rome diagnostic criteria have a 98% positive predictive value for IBS


#### DIFFERENTIAL DIAGNOSES

In patients with alarm features, or patients who do not meet diagnostic criteria for IBS, further investigation of the following may be warranted:

- Abdominal wall pain
- · Bile acid malabsorption
- Celiac disease
- Colon cancer
- Defecatory disorder
- Dyspepsia
- Endometriosis
- · Inflammatory bowel disease
- Microscopic colitis
- Narcotic bowel syndrome
- Small intestinal bacterial overgrowth

### C BRISTOL STOOL FORM SCALE FOR IBS SUBTYPING\*

IBS subtypes are based on the predominant stool form on days with at least one abnormal bowel movement. Threshold for classification of IBS subtypes based on proportion of abnormal bowel movements.



References: 1. Lacy BE et al. *Gastroenterology*. 2016;150(6):1393-1407. doi:10.1053/j.gastro.2016.02.031 2. Lacy BE et al. *Am J Gastroenterol*. 2021;116(1):17-44. doi:10.14309/ ajg.00000000001036 3. Lacy BE. *Int J Gen Med*. 2016;9:7-17. doi:10.2147/IJGM.S93698 4. Black CJ. *Aliment Pharmacol Ther*. 2021;54(suppl 1):S33–S43. doi:10.1111/apt.16597 5. Farmer AD et al. *CMAJ*. 2020;192:E275-E282. doi:10.1503/cmaj.190716 6. Moayyedi P et al. *United European Gastroenterol J*. 2017;5(6):773-788. doi:10.1177/2050640617731968 7. Drossman DA et al. *Gastroenterology*. 2022;162(3):675-679. doi:10.1053/j.gastro.2021.11.019



© 2022 AbbVie and Ironwood Pharmaceuticals, Inc. All rights reserved. Ironwood® and its three-leaf design are registered trademarks of Ironwood Pharmaceuticals, Inc. ABBV-US-00715-MC October 2022 \*Patients who meet the diagnostic criteria for IBS but whose bowel habits cannot be accurately categorized into one of these three groups should be categorized as IBS-Unclassified. Adapted with permission from © 2006 Rome Foundation. This diagnostic pathway is provided as a reference tool only and is not a substitute for clinical judgment. Each healthcare provider is solely responsible for any decisions made or actions taken in reliance of this information.